Literature DB >> 29175414

The Effect of Drug Content Reduction on the In Vitro and In Vivo Properties of Levonorgestrel-Releasing Intravaginal Rings.

Rüdiger Nave1, Tero Jalkanen2, Christine Talling2, Masato Kaneko3, Shunji Matsuki4, Joachim Höchel5.   

Abstract

Intravaginal rings (IVRs) are an option for continuous administration of drugs in women. However, a considerable amount of excess drug often remains in the ring upon removal. The current study focuses on comparing 2 IVRs releasing levonorgestrel (LNG). Both formulations were designed to release 40 μg of LNG daily, however, with a significant difference in the total amount of drug (10.6 vs. 176.9 mg). Numerical simulations and in vitro release rate testing were utilized in designing the IVRs and confirming the similarity of drug release. Moreover, a pharmacokinetic (PK) study was performed in 13 healthy Japanese women to investigate both formulations during the intended wearing period of 28 days. The primary PK metrics was the average concentration of LNG in plasma at defined time points under stable conditions. Statistical evaluation of the ratio of the main PK metrics indicated values almost in the bioequivalence range. Furthermore, drug content determinations for used and unused IVRs were analyzed for confirming the expected drug delivery in vivo. In summary, it was shown that with proper design, even major differences in the total drug content of IVR formulations might not result in significant effects in the in vitro and in vivo release properties.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  absorption; bioavailability; clinical pharmacokinetics; controlled release/delivery; dissolution rate; formulation; hormones; polymeric drug delivery systems

Mesh:

Substances:

Year:  2017        PMID: 29175414     DOI: 10.1016/j.xphs.2017.11.009

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial.

Authors:  Rüdiger Nave; Uwe Mellinger; Stefan Klein; Joachim Höchel; Heinz Schmitz
Journal:  J Clin Pharmacol       Date:  2019-02-21       Impact factor: 3.126

2.  Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective.

Authors:  Rüdiger Nave
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

3.  Development of Hormonal Intravaginal Rings: Technology and Challenges.

Authors:  Fojan Rafiei; Hadi Tabesh; Shayan Farzad; Farah Farzaneh; Maryam Rezaei; Fateme Hosseinzade; Khosrow Mottaghy
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

Review 4.  In Vitro Methods for Evaluating Drug Release of Vaginal Ring Formulations-A Critical Review.

Authors:  Katharina Tietz; Sandra Klein
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.